Trial Profile
A Randomized, Double Blind, Parallel Group, Multicenter Efficacy and Safety Study of SEP-225289 Versus Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Dasotraline (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 09 May 2018 Results (n=973) of pooled post-hoc analysis from two double blind studies (NCT01692782 and NCT02276209) presented at the 171st Annual Meeting of the American Psychiatric Association
- 23 Nov 2015 Results published in the Clinical Drug Investigation
- 11 Dec 2014 Results published in Sunovion Pharmaceuticals media release.